Rey-Carrizo M et al. (2013), 3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane de...

XB-ART-47773

J Med Chem 2013 Nov 27;5622:9265-74. doi: 10.1021/jm401340p.

Show Gene links Show Anatomy links

3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.

Rey-Carrizo M , Torres E , Ma C , Barniol-Xicota M , Wang J , Wu Y , Naesens L , DeGrado WF , Lamb RA , Pinto LH , Vázquez S .

???displayArticle.abstract???
We have synthesized and characterized a series of compounds containing the 3-azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane scaffold designed as analogues of amantadine, an inhibitor of the M2 proton channel of influenza A virus. Inhibition of the wild-type (WT) M2 channel and the amantadine-resistant A/M2-S31N and A/M2-V27A mutant ion channels were measured in Xenopus oocytes using two-electrode voltage clamp (TEV) assays. Most of the novel compounds inhibited the WT ion channel in the low micromolar range. Of note, several compounds inhibited the A/M2 V27A mutant ion channel, one of them with submicromolar IC50. None of the compounds was found to inhibit the S31N mutant ion channel. The antiviral activity of three novel dual WT and A/M2-V27A channels inhibitors was confirmed by influenza virus yield assays.

???displayArticle.pubmedLink??? 24237039
???displayArticle.pmcLink??? PMC3889466
???displayArticle.link??? J Med Chem
???displayArticle.grants??? [+]

References [+] :

Ayats, Alternative syntheses of the new D2d symmetric tetramethyl tricyclo- [3.3.0.0(3,7)]octane-1,3,5,7-tetracarboxylate. 2003, Pubmed

Ayats, Alternative syntheses of the new D2d symmetric tetramethyl tricyclo- [3.3.0.0(3,7)]octane-1,3,5,7-tetracarboxylate. 2003, Pubmed
Balannik, Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. 2009, Pubmed , Xenbase
Balannik, Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel. 2010, Pubmed , Xenbase
Baz, Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. 2009, Pubmed
Bright, Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. 2006, Pubmed
Cady, Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. 2011, Pubmed
Camps, Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. 2008, Pubmed
Duque, Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. 2011, Pubmed , Xenbase
Fiore, Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. 2007, Pubmed
Furuse, Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance. 2009, Pubmed
Grambas, Maturation of influenza A virus hemagglutinin--estimates of the pH encountered during transport and its regulation by the M2 protein. 1992, Pubmed
Gu, Structural comparison of the wild-type and drug-resistant mutants of the influenza A M2 proton channel by molecular dynamics simulations. 2013, Pubmed
Kolocouris, Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues. 2008, Pubmed
Lamb, Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. 1985, Pubmed
Lamb, Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. 1981, Pubmed
Ma, Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus. 2008, Pubmed , Xenbase
Moscona, Global transmission of oseltamivir-resistant influenza. 2009, Pubmed
Naesens, Anti-influenza virus activity and structure-activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. 2009, Pubmed
Pielak, Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel. 2010, Pubmed
Stevaert, Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease. 2013, Pubmed
Takeda, Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. 2002, Pubmed
Torres, Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. 2012, Pubmed
Torres, Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds. 2013, Pubmed
Vanderlinden, Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. 2010, Pubmed
Vanderlinden, Emerging antiviral strategies to interfere with influenza virus entry. 2014, Pubmed
Wang, Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. 2013, Pubmed
Wang, Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. 2011, Pubmed
Wang, Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. 2011, Pubmed
Wang, Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. 2013, Pubmed
Wang, Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. 1993, Pubmed , Xenbase
Williams, Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR. 2013, Pubmed
Zhirnov, Solubilization of matrix protein M1/M from virions occurs at different pH for orthomyxo- and paramyxoviruses. 1990, Pubmed